These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37848636)

  • 1. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database.
    Park S; Kim Y; Lee GH; Choi SA
    Sci Rep; 2023 Oct; 13(1):17607. PubMed ID: 37848636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.
    Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B
    Clin Transl Allergy; 2021 Jun; 11(4):e12038. PubMed ID: 34123366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics for asthma and risk of pneumonia.
    Matera MG; Ora J; Calzetta L; Rogliani P; Cazzola M
    J Asthma; 2024 Sep; 61(9):905-911. PubMed ID: 38294705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Omalizumab Related to Ear and Labyrinth Disorders? A Disproportionality Analysis Based on a Global Pharmacovigilance Database.
    Park HT; Park S; Jung YW; Choi SA
    Diagnostics (Basel); 2022 Oct; 12(10):. PubMed ID: 36292123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics in allergic rhinitis.
    Bayar Muluk N; Cingi C
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases.
    Jackson K; Bahna SL
    Expert Rev Clin Immunol; 2020 Mar; 16(3):311-319. PubMed ID: 31994421
    [No Abstract]   [Full Text] [Related]  

  • 9. Biological therapy-associated adverse reactions in asthma: analysis of reporting to the Portuguese pharmacovigilance system.
    Sousa J; Taborda-Barata L; Monteiro C
    Expert Opin Drug Saf; 2020 Jan; 19(1):99-106. PubMed ID: 31661986
    [No Abstract]   [Full Text] [Related]  

  • 10. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
    Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
    Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
    Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-IL5 therapies for asthma.
    Farne HA; Wilson A; Powell C; Bax L; Milan SJ
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.
    Park S; Park SH; Byun YJ; Choi SA
    PLoS One; 2022; 17(7):e0270906. PubMed ID: 35895603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of biological therapy in elderly patients with severe asthma.
    Mir-Ihara P; Narváez-Fernández E; Domínguez-Ortega J; Entrala A; Barranco P; Luna-Porta JA; Romero D; Villamañán E; Losantos-García I; Quirce S
    J Asthma; 2022 Nov; 59(11):2218-2222. PubMed ID: 34889165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Stack TJ; Kim S; Lamb MM; Mohammad I; Zeatoun A; Lopez E; Klatt-Cromwell C; Thorp BD; Ebert CS; Senior BA; Kimple AJ; Alicea D
    ORL J Otorhinolaryngol Relat Spec; 2023; 85(6):329-339. PubMed ID: 37963438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
    Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of biologics used in the treatment of asthma.
    Neunie OAM; Rabbani W; Baker D; Chambers ES; Pfeffer PE; Kang AS
    Hum Antibodies; 2024; 32(3):121-128. PubMed ID: 38905039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A drug safety review of treating eosinophilic asthma with monoclonal antibodies.
    Mitchell P; Leigh R
    Expert Opin Drug Saf; 2019 Dec; 18(12):1161-1170. PubMed ID: 31594389
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-World Studies of Biologics for the Treatment of Moderate-to-Severe Asthma.
    Desai M; Haines A; Oppenheimer JJ
    Immunol Allergy Clin North Am; 2024 Nov; 44(4):737-750. PubMed ID: 39389721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of refractory asthma with antibodies].
    Lommatzsch M
    Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.